|By PR Newswire||
|September 3, 2014 03:00 PM EDT||
WOODBRIDGE, Ontario, September 3, 2014 /PRNewswire/ --
Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease ("CVD") and overall health, announced today that the cardio-protective effects of Pivotal's unique Omega-3 formulation commercialized as VASCAZEN® was presented at the 2014 Annual Scientific Meeting of the European Society of Cardiology ("ESC") Congress 2014 in Barcelona, Spain, by Rasul et al. from the Laboratory of Biophotonics and Pharmacology of the University of Strasbourg, France.
The presented poster, entitled "Chronic oral intake of the omega 3 optimized formulation EPA:DHA 6:1 protects against angiotensin II-induced hypertension and endothelial dysfunction in rats," indicated that chronic intake of VASCAZEN®'s EPA:DHA 6:1 prevented the development of hypertension and endothelial dysfunction in a rodent model. The vasoprotective and antihypertensive effects of VASCAZEN® is mediated by an improvement of both the nitric oxide (NO) and the EDH-mediated relaxations as well as a reduction of endothelium-dependent contractile response.
"These findings show that formulation, purity and dose plays a significant role in biological activity," said Dr. George Jackowski, Chief Scientific Officer. "Until now, many Cardiologists believed that all Omega-3s had similar vasodilatory effects, regardless of formulation. We are very pleased to have had this opportunity to educate the attendees of the ESC Congress about the unique VASCAZEN® EPA:DHA 6:1 formulation and its proven clinical superiority over other existing commercial products in the marketplace in terms of sustained coronary vasodilation (i.e. increase of blood flow)."
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a publicly traded (OTCQX:PVTTF; CSE:PVO), specialty pharmaceutical company with a focus on cardiovascular disease and overall health. Pivotal Therapeutics' lead product VASCAZEN® is a prescription only medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications. OMAZEN®is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in each capsule for the maintenance of good health. OMAZEN® is a patented product available for sale and distribution in Canada.
VASCAZEN® is currently available in the U.S. as a prescription only medical food specifically formulated for the dietary management of an Omega-3 deficiency in cardiovascular patients. VASCAZEN® is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid formulation, protected by a series of both U.S. and foreign patents.
VASCAZEN® has been clinically shown to correct an Omega-3 deficiency within eight weeks of treatment with positive concomitant effects on the lipid profiles, mainly a 48% reduction of triglycerides and an increase of HDL without negative impact on the LDL-C lipid profile. VASCAZEN®'s results were achieved with a dose of 3 grams of EPA and DHA per day of a prescription grade, high purity, uniquely formulated Omega-3.
The information contained in this document is as of September 3, 2014. This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause Pivotal's actual results to differ materially from those projected in such forward-looking statements. These statements can be identified by the use of words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe", "project", "potential", and similar expressions with any discussion of future operating or financial performance or events. In particular, factors that could cause actual results to differ materially from those in forward looking statements include the following: Pivotal's inability to obtain additional financing on acceptable terms; growth in costs and expenses; inability to compete with others who provide comparable products; risk that the Company's products will not gain widespread market acceptance; risks relating to the Company's ability to maintain its CSE listing. Forward-looking statements speak only as of the date made and are not guarantees of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this document as a result of new information or future events or developments. The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this information.
For further information:
Communications and Public Relations Manager
Phone: +1-905-856-9797 ext. 231
E-Mail: [email protected]
Investor & Media Contact:
President, Kilmer Lucas Inc.
E-Mail: [email protected]
Oct. 24, 2016 02:45 AM EDT Reads: 1,096
Oct. 24, 2016 02:30 AM EDT Reads: 1,047
Oct. 24, 2016 02:15 AM EDT Reads: 823
Oct. 24, 2016 01:15 AM EDT Reads: 1,886
Oct. 24, 2016 01:15 AM EDT Reads: 3,920
Oct. 24, 2016 01:00 AM EDT Reads: 780
Oct. 24, 2016 01:00 AM EDT Reads: 3,570
Oct. 24, 2016 12:45 AM EDT Reads: 2,481
In past @ThingsExpo presentations, Joseph di Paolantonio has explored how various Internet of Things (IoT) and data management and analytics (DMA) solution spaces will come together as sensor analytics ecosystems. This year, in his session at @ThingsExpo, Joseph di Paolantonio from DataArchon, will be adding the numerous Transportation areas, from autonomous vehicles to “Uber for containers.” While IoT data in any one area of Transportation will have a huge impact in that area, combining sensor...
Oct. 24, 2016 12:45 AM EDT Reads: 758
Oct. 24, 2016 12:45 AM EDT Reads: 1,347
Oct. 24, 2016 12:45 AM EDT Reads: 963
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smar...
Oct. 24, 2016 12:15 AM EDT Reads: 881
@DevOpsSummit has been named the ‘Top DevOps Influencer' by iTrend. iTrend processes millions of conversations, tweets, interactions, news articles, press releases, blog posts - and extract meaning form them and analyzes mobile and desktop software platforms used to communicate, various metadata (such as geo location), and automation tools. In overall placement, @DevOpsSummit ranked as the number one ‘DevOps Influencer' followed by @CloudExpo at third, and @MicroservicesE at 24th.
Oct. 24, 2016 12:00 AM EDT Reads: 3,974
@ThingsExpo has been named the Top 5 Most Influential M2M Brand by Onalytica in the ‘Machine to Machine: Top 100 Influencers and Brands.' Onalytica analyzed the online debate on M2M by looking at over 85,000 tweets to provide the most influential individuals and brands that drive the discussion. According to Onalytica the "analysis showed a very engaged community with a lot of interactive tweets. The M2M discussion seems to be more fragmented and driven by some of the major brands present in the...
Oct. 23, 2016 11:45 PM EDT Reads: 11,357
Effectively SMBs and government programs must address compounded regulatory compliance requirements. The most recent are Controlled Unclassified Information and the EU’s GDPR have Board Level implications. Managing sensitive data protection will likely result in acquisition criteria, demonstration requests and new requirements. Developers, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by incorporating changes.
Oct. 23, 2016 11:15 PM EDT Reads: 1,646